Contract award and update

RNS Number : 5736R

Physiomics PLC

30 June 2020

 

30 June 2020

Physiomics plc

("Physiomics") or (the "Company")

Contract award and update

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by existing client Bicycle Therapeutics plc (Nasdaq: BCYC) ("Bicycle").  The project involves advanced translational pharmacokinetic modelling of one of Bicycle's pipeline assets and represents the fourth Bicycle asset for which the Company has provided modelling support.  The project is likely to last around two months.

In addition, the Company would like to confirm that it is in the late stages of agreeing a contract with the potential new large pharmaceutical client that was originally referred to in its placing announcement of 27 May 2020.  As noted in that announcement, the project would take two of our technical staff around five months to complete.  The Company will provide a further update on this in due course, as and when appropriate.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC ) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

 

END

 

 

UPDEADKEDAKEEFA